TD Cowen Reiterates Buy Rating on Avidity Biosciences (RNA)

October 4, 2024 7:26 AM EDT Send to a Friend
TD Cowen analyst Ritu Baral reiterated a Buy rating and $56.00 price target on Avidity Biosciences (NASDAQ: RNA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login